A genetic polymorphism in P2RY1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy

• Published in: Scientific reports Vol. 11; no. 1; p. 12522
• Main Authors: Ueda, Yu, Li, Ronald H. L., Nguyen, Nghi, Ontiveros, Eric S., Kovacs, Samantha L., Oldach, Maureen S., Vernau, Karen M., Court, Michael H., Stern, Joshua A.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 15.06.2021; Nature Publishing Group
• Subjects: Adenosine; Adenosine diphosphate; Blood; Blood platelets; Cardiomyopathy; Clopidogrel; Cytochrome; Cytochrome P450; Flow cytometry; Gene polymorphism; Humanities and Social Sciences; Isoenzymes; Metabolites; multidisciplinary; Platelets; Polymorphism; Science; Science (multidisciplinary); Single-nucleotide polymorphism; Thromboembolism
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-91372-3

Clopidogrel is converted to its active metabolite by cytochrome P450 isoenzymes and irreversibly inhibits platelet activation by antagonizing the adenosine-diphosphate (ADP) receptor. It is frequently used in cats with hypertrophic cardiomyopathy (HCM) to prevent thromboembolic complications. However, significant interpatient variability of the response to clopidogrel therapy has been suspected. In this study, we assessed the impact of single nucleotide polymorphisms (SNPs) within ADP receptor ( P2RY1, P2RY12 ) and cytochrome P450 isoenzyme ( CYP2C41 ) genes on platelet inhibition by clopidogrel administration in cats with HCM. Forty-nine cats completed the study, and blood samples were obtained before and after clopidogrel therapy to assess the degree of platelet inhibition based on flow cytometry and whole blood platelet aggregometry. Plasma concentrations of clopidogrel metabolites were measured after the last dose of clopidogrel. Whole blood platelet aggregometry revealed a significant reduction of platelet inhibition by clopidogrel in cats with the P2RY1:A236G and the P2RY12:V34I variants. The association with the P2RY1:A236G variant and clopidogrel resistance remained significant after adjustment for multiple comparisons. This study demonstrated that a genetic polymorphism in the P2RY1 gene altered response to clopidogrel therapy and suggests that clinicians may consider alternative or additional thromboprophylactic therapy in cats with the P2RY1:A236G variant.